Deep Genomics utilizes a proprietary AI platform to analyze complex RNA biology data, identifying novel therapeutic targets for genetic conditions. By streamlining the drug discovery process, the company aims to develop RNA therapies that can precisely target genetic causes, significantly reducing the time and cost associated with traditional methods.
Funding
$180M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SVFounders
Product
Problem
Traditional drug discovery methods for genetic conditions are slow and costly due to the vast complexity of RNA biology data. Identifying novel therapeutic targets and evaluating potential drug candidates requires extensive time and resources.
Solution
Deep Genomics offers an AI platform designed to analyze complex RNA biology data to identify novel therapeutic targets for a wide range of genetic conditions. The platform leverages data-driven prediction, positive feedback loops, and scale to accelerate the drug discovery process. By untangling the complexities of RNA biology, the AI platform evaluates thousands of possibilities to pinpoint the most promising therapeutic candidates. The company aims to develop RNA therapies that precisely target the genetic causes of diseases.
Target Audience
The primary audience includes pharmaceutical companies and research institutions focused on developing RNA therapies for genetic conditions.
Features
- Proprietary AI platform for data-driven prediction of RNA-based therapeutic targets.
- Foundation Model for RNA Biology (BigRNA) to expand the number of mechanisms and genetic variants that can be pursued.
- Capability to identify novel targets and therapies for complex genetic diseases.
- Ability to evaluate thousands of therapeutic candidates to identify the most promising options.